Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

59.43USD
2 Dec 2016
Change (% chg)

$0.27 (+0.46%)
Prev Close
$59.16
Open
$59.19
Day's High
$60.00
Day's Low
$58.95
Volume
8,020,668
Avg. Vol
7,220,830
52-wk High
$68.12
52-wk Low
$50.71

Latest Key Developments (Source: Significant Developments)

CHMP recommends EU approval of Venclyxto in hard-to-treat CLL-Roche
Friday, 14 Oct 2016 07:16am EDT 

Roche Holding AG :Says : roche announces CHMP recommendation for eu approval of venclyxto for people with hard-to-treat chronic lymphocytic leukaemia.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 07:00am EDT 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

U.S. FDA approves Amjevita, a biosimilar to Humira
Friday, 23 Sep 2016 04:47pm EDT 

U.S. FDA : Fda approves Amjevita, a biosimilar to Humira .Approved Amjevita (Adalimumab-Atto) as a biosimilar to Humira (Adalimumab) for multiple inflammatory diseases.  Full Article

arGEN X cash position at June end doubles to 108.7 mln euros
Friday, 26 Aug 2016 01:00am EDT 

arGEN X BV : Q2 revenue is 5.7 million euros ($6.4 million) versus 2.7 million euros year ago . Q2 total operating income is 7.0 million euros versus 4.3 million euros a year ago . Q2 net loss is 7.4 million euros versus loss of 7.0 million euros a year ago . At June 30 cash position of 108.7 million euros (cash, cash-equivalents and financial assets) versus 50.5 million euros a year ago . Phase 2 study in first auto-immune indication planned to start by year-end . Cash position strengthened by $40 million upfront payment from AbbVie and 30 million euros private placement .On ARGX-110 t-cell lymphoma (TCL) - top line date to be presented by end 2016, first combination study to start in H2 2016.  Full Article

AbbVie CEO says no longer looking for a big acquisition: Conf Call
Friday, 29 Jul 2016 10:24am EDT 

: Abbvie Expects Mid Teen percentage prescription volume growth for humira: conf call . Abbvie ceo says indirect biosimilar competition for humira has been as expected in the quarter: conf call . Abbvie expects 2016 revenue of about $26 billion : conf call . Abbvie ceo says he remains confident on the ip protection on humira: conf call . Abbvie ceo says will consider opportunities that are complementary to their portfolio, but is no longer pursuing a big acquisition : conf call Further company coverage: [ABBV.N] (Bengaluru Newsroom +1-646-223-8780).  Full Article

Abbvie Q2 adjusted EPS $1.26
Friday, 29 Jul 2016 07:38am EDT 

Abbvie : FY 2016 earnings per share view $4.75 -- Thomson Reuters I/B/E/S . Reports Second Quarter 2016 financial results . Q2 adjusted earnings per share $1.26 . Q2 GAAP earnings per share $0.98 . Q2 revenue $6.45 billion versus I/B/E/S view $6.2 billion . Q2 earnings per share view $1.20 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $4.73 to $4.83 . Sees FY 2016 GAAP earnings per share $3.82 to $3.92 .Q2 total Humira sales $4,149 million versus. $3,537 million last year.  Full Article

AbbVie initiates late stage study of venetoclax in patients with relapsed or refractory multiple myeloma
Thursday, 28 Jul 2016 05:30pm EDT 

Abbvie Inc : Venetoclax is being developed by abbvie and genentech, a member of roche group .Abbvie announces initiation of phase 3 study of venetoclax in patients with relapsed or refractory multiple myeloma.  Full Article

X-Chem, AbbVie enter into drug discovery partnership
Tuesday, 26 Jul 2016 08:15am EDT 

X-Chem Inc : X-Chem and abbvie enter into multi-target drug discovery partnership .Chem - financial terms were not disclosed..  Full Article

Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
Monday, 25 Jul 2016 04:00am EDT 

Abbvie Inc : CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C with compensated cirrhosis (child-pugh a) .Says VIEKIRAX with RBV is currently approved in European Union for GT4 patients with compensated cirrhosis for 24 weeks.  Full Article

Ablynx CEO sees potential multibillion-dollar opportunity for drug
Thursday, 7 Jul 2016 04:22am EDT 

Ablynx CEO Edwin Moses told Reuters: Sales opportunity for vobarilizumab could be in "billions" of dollars in rheumatoid arthritis & other diseases . AbbVie will decide later in 2016 whether to license vobarilizumab, after second RA trial results expected in August Further company coverage: [ABLX.BR] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.